Statins as adjunct therapy in COPD: is it time to target innate immunity and cardiovascular risk?

Eur Respir J. 2021 Jul 29;58(1):2100342. doi: 10.1183/13993003.00342-2021. Print 2021 Jul.

Authors

Robert P Young¹, Raewyn J Scott²

Affiliations

¹ Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand [email protected].
² Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

PMID: 34326175
DOI: 10.1183/13993003.00342-2021

No abstract available

Publication types

Editorial
Comment

MeSH terms

Cardiovascular Diseases* / drug therapy
Heart Disease Risk Factors
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Immunity, Innate
Pulmonary Disease, Chronic Obstructive* / drug therapy
Risk Factors

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors